Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of Chicago
Big Ten Cancer Research Consortium
Ossium Health, Inc.
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC
Fondazione Italiana Linfomi - ETS
M.D. Anderson Cancer Center
Acerta Pharma BV
University of Washington
GlaxoSmithKline
Takeda
UNC Lineberger Comprehensive Cancer Center
Immunitas Therapeutics
National Institutes of Health Clinical Center (CC)
Emory University
University of Washington
AstraZeneca
Thomas Jefferson University
AIDS Malignancy Consortium
M.D. Anderson Cancer Center
Instituto Nacional de Cancer, Brazil
Assiut University
VectivBio AG
Takeda
Roswell Park Cancer Institute
Akeso
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
National Cancer Institute (NCI)
Chinese PLA General Hospital
St. Petersburg State Pavlov Medical University
Atara Biotherapeutics
Columbia University
Seagen Inc.
New York Medical College
Memorial Sloan Kettering Cancer Center
Italfarmaco
The Lymphoma Academic Research Organisation
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Spectrum Pharmaceuticals, Inc
Gamida Cell ltd
Columbia University
Italfarmaco
Weill Medical College of Cornell University
M.D. Anderson Cancer Center
Novartis
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Mayo Clinic